Nigel A J McMillan
Overview
Explore the profile of Nigel A J McMillan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
1228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chowdhury F, Akter A, Bhuiyan T, Biswas R, Firoj M, Tauheed I, et al.
Front Immunol
. 2023 Jan;
13:1067737.
PMID: 36618409
Background: Immune responses that target sialidase occur following natural cholera and have been associated with protection against cholera. Sialidase is a neuraminidase that facilitates the binding of cholera toxin (CT)...
12.
Idres Y, Lai A, McMillan N, Idris A
Virus Genes
. 2022 Dec;
59(2):312-316.
PMID: 36474086
Clinical and pre-clinical work for a number of cancer types has demonstrated relatively positive outcomes and effective tumour regression when the level and function of p53, a well-established tumour suppressor,...
13.
Ferreira D, Idris A, McMillan N
J Med Virol
. 2022 Oct;
95(1):e28260.
PMID: 36305515
Several viruses are known to be associated with the development of certain cancers, including human papilloma virus (HPV), an established causative agent for a range of anogenital and head and...
14.
Tang K, Weeramange C, Vider J, Hartel G, West N, McMillan N, et al.
Oral Oncol
. 2022 Oct;
135:106215.
PMID: 36274347
No abstract available.
15.
Ferreira D, McMillan N, Idris A
Biomed Pharmacother
. 2022 Oct;
155:113782.
PMID: 36271562
The major HPV oncogenes, E6 and E7, are known for its notoriety in driving the carcinogenic process in human papilloma virus (HPV) driven cancers. It is well-established that the removal...
16.
Islam M, Date K, Khan A, Bhuiyan T, Khan Z, Ahmed S, et al.
Clin Infect Dis
. 2022 Sep;
76(2):263-270.
PMID: 36136760
Background: Cholera remains a public health threat for low- and middle-income countries, particularly in Asia and Africa. Shanchol™, an inactivated oral cholera vaccine (OCV) is currently in use globally. OCV...
17.
Johnson N, Salinas Montalvo A, McMillan N
JAMA Otolaryngol Head Neck Surg
. 2022 Aug;
148(10):992-993.
PMID: 36006627
No abstract available.
18.
Isaacs A, Amarilla A, Aguado J, Modhiran N, Albornoz E, Baradar A, et al.
Front Immunol
. 2022 Jun;
13:926262.
PMID: 35757714
Since the start of the COVID-19 pandemic, multiple waves of SARS-CoV-2 variants have emerged. Of particular concern is the omicron variant, which harbors 28 mutations in the spike glycoprotein receptor...
19.
Chowdhury F, Ross A, Islam M, McMillan N, Qadri F
Clin Microbiol Rev
. 2022 Jun;
35(3):e0021121.
PMID: 35726607
Cholera, caused by Vibrio cholerae, persists in developing countries due to inadequate access to safe water, sanitation, and hygiene. There are approximately 4 million cases and 143,000 deaths each year...
20.
Idres Y, McMillan N, Idris A
Mol Diagn Ther
. 2022 Apr;
26(3):301-308.
PMID: 35380358
Despite a vaccine being available, human papillomavirus virus (HPV)-driven cancers remain the ninth most prevalent cancers globally. Current therapies have significant drawbacks and often still lead to poor prognosis and...